Neuraxis vs Nuwellis
NRXS and NUWE side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How NRXS and NUWE compare
Neuraxis is the larger company, worth 27 times as much as Nuwellis ($72.2M against $2.7M).
Nuwellis scores higher on the StockData Score (10 against 0 for Neuraxis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | NRXS | NUWE |
|---|---|---|
| Size and price | ||
| Market cap | $72.2M | $2.7M |
| Share price | $5.75 | $5.03 |
| Change, 1 year | 139% | −99.4% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | 0.91 | – |
| Employees | 24 | 24 |
| StockData Score | ||
| Total score | 0 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 0 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.3× |
| P/B | – | 0.3× |
| FCF yield | – | −452% |
| Fair value | – | $27.50 |
| Margin of safety | – | 81.7% |
| Growth | ||
| Revenue growth (TTM) | – | 10.3% |
| Revenue growth, 5Y average | – | 2.1% |
| Profitability | ||
| Gross margin | – | 70.8% |
| Operating margin | – | −136% |
| Net margin | – | −153% |
| FCF margin | – | −137% |
| Return on equity | – | −200% |
| Return on invested capital | – | −816% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | – | 3.99 |
| Altman Z-score | – | −35.20 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 21.7% | 3.9% |
| Held by insiders | 39.9% | – |
| Insider net buying, 12 months | $1.4M | – |
| Short interest, % of float | 6.0% | – |
Go deeper
- NRXS stock overview
- NRXS income statement
- NRXS valuation and score
- NUWE stock overview
- NUWE income statement
- NUWE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.